Seth Klarman’s portfolio: Baupost Group 13F holdings

Quarterly SEC 13F-HR filingsCIK 0001061768Latest: Q2 2026

Q2 2017 filing in brief

In its Q2 2017 13F, filed August 11, 2017, Baupost Group reported $8.8B across 41 US positions. The largest: LNG (11.5%), SYF (10.0%), VSAT (9.9%), COLONY NORTHSTAR INC (7.7%), ALLERGAN PLC (6.8%). In the quarter it opened 4 positions, sold out of 6, added to 7 and trimmed 5; positions opened and sold out came to 9.1% of the portfolio's value.

Methodology

Holdings come from the manager’s Form 13F-HR filings on SEC EDGAR, with amendments applied. Values and shares are reported at quarter-end; the filing date is when the report became public. These disclosures show reported long positions and listed options, not the manager’s entire portfolio or its trades since quarter-end.

Quarterly changes compare shares with the immediately preceding quarter on file. New and exited positions appear or disappear; added and trimmed positions change their share count by more than 1%. A share change can also reflect a stock split or other corporate action.

Opened and sold out is the value of new positions plus the prior value of exited positions, divided by the average of the two quarters’ reported portfolio values. It excludes changes to positions still held. Reported value growth includes price changes and is not a measure of investment performance. Largest-five and largest-ten weights exclude options.

Holdings

Filed Aug 11, 2017

  • 4 New
  • 7 Added
  • 5 Trimmed
  • 6 Exited

41 positions at June 30, 2017. Q/Q change compares shares with the preceding quarter.

RowTickerIssuerStatus
1LNGCHENIERE ENERGY INC$1.0B20.7M11.53%−4.6%Trimmed
2SYFSYNCHRONY FINL$874M29.3M9.98%+65.8%Added
3VSATVIASAT INC$871M13.2M9.95%0.0%Held
4—COLONY NORTHSTAR INC$675M47.9M7.71%0.0%Held
5—ALLERGAN PLC$591M2.4M6.76%0.0%Held
6QRVOQORVO INC$570M9.0M6.51%+25.3%Added
7—TWENTY FIRST CENTY FOX INC$542M19.1M6.20%0.0%Held
8ARANTERO RES CORP$458M21.2M5.23%+45.9%Added
9—THERAVANCE BIOPHARMA INC$369M9.3M4.22%0.0%Held
10PBFPBF ENERGY INC$350M15.7M4.00%0.0%Held
11—DELL TECHNOLOGIES INC$345M5.7M3.95%0.0%Held
12QCOMQUALCOMM INC$288M5.2M3.29%0.0%Held
13—TWENTY FIRST CENTY FOX INC$203M7.3M2.32%0.0%Held
14—KERYX BIOPHARMACEUTICALS INC$186M25.8M2.13%0.0%Held
15—EXPRESS SCRIPTS HLDG CO$163M2.6M1.86%+108.1%Added
16CAHCARDINAL HEALTH INC$158M2.0M1.81%+97.1%Added
17VRTVEURVERITIV CORP$137M3.0M1.57%0.0%Held
18—FORWARD PHARMA A/S$129M6.4M1.48%+14.1%Added
19CARAVIS BUDGET GROUP$109M4.0M1.25%—New
20ATRAGBXATARA BIOTHERAPEUTICS INC$75M5.4M0.86%0.0%Held
21—CHIPMOS TECHNOLOGIES INC$69M3.5M0.79%0.0%Held
22—SILVER RUN ACQUISITION$67M6.6M0.77%—New
23—SPIRIT RLTY CAP INC NEW$67M9.0M0.76%—New
24PRTKEURPARATEK PHARMACEUTICALS INC$58M2.4M0.66%+17.1%Added
25—GTY TECHNOLOGY HOLDINGS INC$46M4.4M0.53%0.0%Held
26—CONYERS PK ACQUISITION$44M3.7M0.50%0.0%Held
27NGNOVAGOLD RES INC$43M9.5M0.49%0.0%Held
28TBPH 3.25 11/01/23THERAVANCE BIOPHARMA INC$40M30.0M0.46%0.0%Held
29CDEVEURCENTENNIAL RESOURCE DEV INC$37M2.4M0.42%0.0%Held
30—CASCADIAN THERAPEUTICS INC$32M8.7M0.37%0.0%Held
31BATRKLIBERTY MEDIA CORP DELAWARE$31M1.3M0.36%−34.6%Trimmed
32CACCCREDIT ACCEP CORP MICH$25M98.7K0.29%−59.6%Trimmed
33—SABAN CAP ACQUISITION CORP$23M2.3M0.27%0.0%Held
34RUNSUNRUN INC$20M2.8M0.23%0.0%Held
35INVA 2.125 01/15/23THERAVANCE INC$15M17.0M0.18%−24.5%Trimmed
36—AMERICAN INTL GROUP INC$7M354.8K0.09%−71.8%Trimmed
37TMQTRILOGY METALS INC NEW$7M10.6M0.08%0.0%Held
38—OREXIGEN THERAPEUTICS INC$6M2.2M0.07%0.0%Held
39—SILVER RUN ACQUISITION$4M2.2M0.05%—New
40—CONYERS PK ACQUISITION$3M1.2M0.04%0.0%Held
41—SABAN CAP ACQUISITION CORP$1M1.2M0.02%0.0%Held
6 exited positions

Positions held in the preceding quarter and absent from this filing. Values and shares are from the preceding quarter.

TickerIssuerPrevious valuePrevious shares
INVAINNOVIVA INC$160M11.6M
MCKMCKESSON CORP$148M1.0M
—SILVER RUN ACQUISITION$69M6.6M
—LIBERTY INTERACTIVE CORP$66M1.5M
SYTUSDSYNGENTA AG$47M528.0K
ABGAMERISOURCEBERGEN CORP$44M502.5K
Every quarter on file (53)

From the manager’s Form 13F-HR filings on SEC EDGAR, amendments applied. Long US positions only; not a recommendation.